

## Finwire Interview: CEO Anders Weilandt on Chordate Medical's Q2 Report 2024

**Today, August 30th, Chordate's CEO Anders Weilandt presented the company's Q2 report for 2024 on Finwire TV. He also answered questions from viewers and discussed, among other things, the expectations for Switzerland as a new focus market and the results of the company's participation in investor conferences around the world.**

"It's clear that the market is very responsive; it reacts extremely well. I have the impression that it is a decentralized healthcare market where decisions can be made at much lower levels than, for example, in Sweden or England for that matter. And on top of that, we can add that Neurolite, our distributor, are very active in building and penetrating the market. They focus solely on neurology, so they are very knowledgeable and have well-established contacts and good trust from the healthcare side. I expect things to happen relatively frequently in Switzerland."

"What has opened up through the conferences is a network of contacts that we were looking for in connection with the final steps in our exit process and our strategy in general. It's important to ensure that the Chordate project and this rather fantastic treatment technology become well-known both among industrial stakeholders and partners, and among financial partners."

Watch the full interview (in Swedish): <https://www.youtube.com/live/fQqlm04dijA>

**For more information, please contact:**

Anders Weilandt, CEO  
[anders.weilandt@chordate.com](mailto:anders.weilandt@chordate.com)  
Cell: +46 733-874277

**About Chordate**

Chordate Medical Holding AB (publ) is a medical technology company that has developed, patented and CE-marked Ozilia® Migraine, a neuromodulation and drug-free treatment technology for chronic migraine and chronic rhinitis. The treatment has clinically proven efficacy according to a recent study, and is marketed in selected markets in the EU and the Middle East. Chordate Medical is listed on Nasdaq First North Growth Market Stockholm (ticker: CMH). Read more at [www.chordate.com](http://www.chordate.com)

The company's Certified Adviser on Nasdaq First North Growth Market Stockholm is Vator Securities AB.

*N.B. The English text is an in-house translation of the original Swedish text. Should there be any disparities between the Swedish and the English text, the Swedish text shall prevail.*

Press Release  
30 August 2024 15:12:00 CEST

**CHORDATE**  
M E D I C A L

---

**Attachments**

[Finwire Interview: CEO Anders Weilandt on Chordate Medical's Q2 Report 2024](#)